SCPS Scopus BioPharma Inc.

3.7
-0.17  -4%
Previous Close 3.87
Open 3.87
52 Week Low 3.79
52 Week High 47.86
Market Cap $67,003,060
Shares 18,094,264
Float 3,829,544
Enterprise Value $67,290,778
Volume 90,521
Av. Daily Volume 380,013
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
DUET-01 (CO-sTiRNA)
B-cell non-Hodgkin lymphoma
Phase 1
Phase 1
Phase 1 data noted PD-1 and CTLA-4 checkpoint inhibitors had limited efficacy while intratumoral administration of DUET-01 resulted in complete lymphoma regression, September 29, 2021.
DUET-02
Genitourinary and head & neck cancers
Phase 1
Phase 1
IND due 4Q 2022. Phase 1 trials beginning in 1Q 2023.

Latest News

  1. NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that, on October 8, 2021, its 2021 Annual Meeting of Stockholders (the "Annual Meeting") was adjourned to 1:00 p.m., Eastern time, on Friday, November 5, 2021, without any business being conducted, pursuant to a Stipulation and Court Order approved by the Delaware Court of Chancery between Scopus and Morris C. Laster, M.D. in connection with Dr. Laster's pending claims against Scopus in the Delaware Court of Chancery. Notwithstanding the Stipulation and Court Order requiring Dr. Laster to cause all shares…

    NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that, on October 8, 2021, its 2021 Annual Meeting of Stockholders (the "Annual Meeting") was adjourned to 1:00 p.m., Eastern time, on Friday, November 5, 2021, without any business being conducted, pursuant to a Stipulation and Court Order approved by the Delaware Court of Chancery between Scopus and Morris C. Laster, M.D. in connection with Dr. Laster's pending claims against Scopus in the Delaware Court of Chancery. Notwithstanding the Stipulation and Court Order requiring Dr. Laster to cause all shares of Scopus common stock held by him to be present in person or by proxy at the Annual Meeting and any adjournments thereof exclusively for the purposes of establishing a quorum at the meeting, Dr. Laster failed to satisfy this requirement by both not attending the Annual Meeting in person and not making his shares present by proxy.

    The adjourned meeting will be held by means of remote communication and can be accessed via the following URL: http://www.cesonlineservices.com/scps21_vm. The record date for the Annual Meeting will remain August 16, 2021.

    Scopus continues to solicit votes from its stockholders with respect to the proposals set forth in Scopus' proxy statement dated September 16, 2021. Proxies previously submitted in respect of the Annual Meeting will be voted at the adjourned Annual Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted and who do not want to change their vote need not take any action.

    Scopus encourages all stockholders who own their shares as of the close of business on August 16, 2021 who have not yet voted to do so as soon as possible. Stockholders who have any questions or require any assistance completing a proxy or voting instruction form or who do not have the required materials, may contact Scopus' proxy solicitor, Morrow Sodali LLC, by calling collect at (203) 561-6945 or toll-free at (800) 662-5200 or by emailing SCPS@investor.morrowsodali.com.

    About Scopus BioPharma

    Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. The company's lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. Additional STAT3-targeting immunotherapy drug candidates include bifunctional antisense and DNA-binding inhibition therapies. The company is also seeking to develop additional drug candidates and to identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions. Receive updates by following Scopus BioPharma on Twitter here.

    Forward-Looking Statements

    This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company's Form 10-K for the fiscal year ended December 31, 2020, as amended, filed with the U.S. Securities and Exchange Commission ("SEC")) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Further, there can be no assurance that the company will identify and/or consummate any transaction relating to any additional technologies.

    Contacts

    Rodd Leeds/David Waldman

    Crescendo Communications, LLC

    Tel: (212) 671-1020

    Email: SCPS@crescendo-ir.com

    Hugh Burns/Delia Cannan/Nicholas Leasure

    Reevemark

    Tel: (212) 433-4600

    Email: scopus@reevemark.com



    Primary Logo

    View Full Article Hide Full Article
  2. NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation.

    In the past several weeks, the shares of Scopus BioPharma have come under attack by abusive short sellers. During this period, the short volume ratio has reached nearly 70% and over 25% of the company's market capitalization has been wiped out. The downward pressure on the trading price of the company's common stock has persisted despite recent positive developments.

    Scopus will not stand idly by while the company and its shareholders are victimized by short selling.

    The investigation by Boies Schiller…

    NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation.

    In the past several weeks, the shares of Scopus BioPharma have come under attack by abusive short sellers. During this period, the short volume ratio has reached nearly 70% and over 25% of the company's market capitalization has been wiped out. The downward pressure on the trading price of the company's common stock has persisted despite recent positive developments.

    Scopus will not stand idly by while the company and its shareholders are victimized by short selling.

    The investigation by Boies Schiller Flexner will be led by former federal prosecutors in the firm's global investigations practice group, including former Assistant United States Attorneys for the Southern District of New York who have substantial experience investigating and prosecuting securities crimes, fraud and RICO violations.

    Boies Schiller Flexner will refer all securities and other violations it uncovers to the appropriate criminal and regulatory authorities and will pursue all legal remedies available to the company.

    About Scopus BioPharma

    Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need.

    Forward-Looking Statements

    This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company's Form 10-K for the fiscal year ended December 31, 2020, as amended, filed with the U.S. Securities and Exchange Commission ("SEC")) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections.

    Contacts

    Rodd Leeds/David Waldman

    Crescendo Communications, LLC

    Tel: (212) 671-1020

    Email: SCPS@crescendo-ir.com

    Hugh Burns/Delia Cannan/Nicholas Leasure

    Reevemark

    Tel: (212) 433-4600

    Email: scopus@reevemark.com



    Primary Logo

    View Full Article Hide Full Article
  3. Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology

    Presentation to include a discussion of preclinical data released at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

    NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it will be presenting at The MicroCap Rodeo's Fall Harvest Best Ideas Conference, which is being held virtually from October 5th through 8th, 2021.

    The company will present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused…

    Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology

    Presentation to include a discussion of preclinical data released at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

    NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it will be presenting at The MicroCap Rodeo's Fall Harvest Best Ideas Conference, which is being held virtually from October 5th through 8th, 2021.

    The company will present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology, which Scopus announced in September 2021.

    Alan Horsager, Ph.D., President — Immuno-Oncology of Scopus and President and Chief Executive Officer of Duet, will be presenting on behalf of the company. The presentation is scheduled for Wednesday, October 6, 2021 at 5:00 PM Eastern Time. The presentation will be webcast live and available for replay here. Management will be available for one-on-one meetings to be held throughout the conference.

    Dr. Horsager recently presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society during which he discussed data from two different studies that suggest that DUET-01 and DUET-02, two of Duet's unique bifunctional oligonucleotides, can expand the reach and efficacy of cancer immunotherapies beyond certain standard-of-care treatments.

    Investors interested in attending the conference can register here. If you are an institutional investor and would like to schedule a one-on-one meeting with the company, please email Angie Goertz at angie.goertz@issuerdirect.com.

    About The MicroCap Rodeo's Fall Harvest Best Ideas Conference

    The MicroCap Rodeo is back with its "Best Ideas" conference. This conference is a virtual conference that brings you the top 36 best ideas from the buy side. Qualified institutional investors recommended each of the 36 companies represented as one of their best ideas.

    About the Duet Platform

    Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Olimmune was acquired by Scopus in June 2021. Duet is a wholly-owned subsidiary of Scopus.

    The Duet Platform is comprised of three distinctive, complementary CpG-STAT3 inhibitors:

    • RNA silencing
    CpG-STAT3siRNA("DUET-01")
    • Antisense
    CpG-STAT3ASO("DUET-02")
    • DNA-binding inhibitor
    CpG-STAT3decoy("DUET-03")

    DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file two INDs for DUET-02 in Q4 2022 in genitourinary and head & neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.

    About Scopus BioPharma

    Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. The company's lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. Additional STAT3-targeting immunotherapy drug candidates include bifunctional antisense and DNA-binding inhibition therapies. In addition, the company is developing additional drug candidates that target the endocannabinoid system, including MRI-1867 for the treatment systemic sclerosis. The company also seeks to identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions. Receive updates by following Scopus BioPharma on Twitter here.

    Forward-Looking Statements

    This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company's Form 10-K for the fiscal year ended December 31, 2020, as amended, filed with the U.S. Securities and Exchange Commission ("SEC")) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Further, there can be no assurance that the company will identify and/or consummate any transaction relating to any additional technologies.

    Contacts

    Rodd Leeds/David Waldman

    Crescendo Communications, LLC

    Tel: (212) 671-1020

    Email: SCPS@crescendo-ir.com

    Hugh Burns/Delia Cannan/Nicholas Leasure

    Reevemark

    Tel: (212) 433-4600

    Email: scopus@reevemark.com



    Primary Logo

    View Full Article Hide Full Article
  4. Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors ("Checkpoint Inhibitors") in lymphoma and prostate tumor models in mice

    Studies indicate Duet's bifunctional oligonucleotides — CpG-STAT3siRNA (DUET-01) and CpG-STAT3ASO (DUET-02) — can expand reach and efficacy of cancer immunotherapies beyond the current standard-of-care treatments

    NEW YORK, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the release of preclinical data being presented at the 17th Annual Meeting of the Oligonucleotide…

    Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors ("Checkpoint Inhibitors") in lymphoma and prostate tumor models in mice

    Studies indicate Duet's bifunctional oligonucleotides — CpG-STAT3siRNA (DUET-01) and CpG-STAT3ASO (DUET-02) — can expand reach and efficacy of cancer immunotherapies beyond the current standard-of-care treatments

    NEW YORK, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the release of preclinical data being presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society.

    Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics and President — Immuno-Oncology of Scopus, is presenting data in talks entitled:

    • Bispecific Oligonucleotide Targeting TLR9 and STAT3 Signaling for B Cell Lymphoma Immunotherapy



    • Bifunctional Oligonucleotides for Systemic Treatment of Immunologically Cold Solid Tumors

    Duet Therapeutics is a wholly-owned subsidiary of Scopus.

    Data from two different studies benchmarked Duet's proprietary bifunctional oligonucleotides, CpG-STAT3siRNA (DUET-01) and CpG-STAT3ASO (DUET-02), against Checkpoint Inhibitors in lymphoma and prostate tumor models in mice.

    Dr. Horsager is presenting results of a study comparing Duet's clinical-stage, siRNA-based molecule, or DUET-01, to Checkpoint Inhibitors in an A20 mouse model of B-cell lymphoma. PD-1 and CTLA-4 Checkpoint Inhibitors had limited efficacy while intratumoral administration of DUET-01 resulted in complete lymphoma regression.

    Dr. Horsager is also presenting results of a study comparing Duet's antisense-based bifunctional molecule, or DUET-02, to both PD-1 and CTLA-4 Checkpoint Inhibitors in a bone localized tumor model of metastatic prostate cancer. Clinical observations have indicated that these prostate tumors are resistant to Checkpoint Inhibitors. By comparison, data collected in the laboratory of Marcin Kortylewski, Ph.D., Duet's Senior Scientific Advisor, DUET-02 monotherapy induced potent antitumor immune responses and resulted in long-term animal survival.

    Overall, the studies indicate that Duet's bifunctional oligonucleotides can expand the reach and efficacy of cancer immunotherapies beyond the current standard-of-care treatments.

    Dr. Horsager stated, "These data show compelling evidence that Duet's bifunctional molecules could expand the use of immunotherapies in the treatment of both hematological malignancies and solid tumors to a larger group of patients. We believe that it is the bifunctionality of the molecules that creates the potential for durable antitumor responses."

    About the Duet Platform

    Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Olimmune was acquired by Scopus in June 2021. Duet is a wholly-owned subsidiary of Scopus.

    The Duet Platform is comprised of three distinctive, complementary CpG-STAT3 inhibitors:

       RNA silencingCpG-STAT3siRNA("DUET-01")
       
       AntisenseCpG-STAT3ASO("DUET-02")
       
       DNA-binding inhibitorCpG-STAT3decoy("DUET-03")

    DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file two INDs for DUET-02 in Q4 2022 in genitourinary and head & neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.

    About Scopus BioPharma

    Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. The company's lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. Additional STAT3-targeting immunotherapy drug candidates include bifunctional antisense and DNA-binding inhibition therapies. In addition, the company is developing additional drug candidates that target the endocannabinoid system, including MRI-1867 for the treatment systemic sclerosis. The company also seeks to identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions. Receive updates by following Scopus BioPharma on Twitter here.

    Forward-Looking Statements

    This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company's Form 10-K for the fiscal year ended December 31, 2020, as amended, filed with the U.S. Securities and Exchange Commission ("SEC")) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Further, there can be no assurance that the company will identify and/or consummate any transaction relating to any additional technologies.

    Contacts

    Rodd Leeds/David Waldman

    Crescendo Communications, LLC

    Tel: (212) 671-1020

    Email: SCPS@crescendo-ir.com

    Hugh Burns/Delia Cannan/Nicholas Leasure

    Reevemark

    Tel: (212) 433-4600

    Email: scopus@reevemark.com

     



    Primary Logo

    View Full Article Hide Full Article
  5. NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that Duet Therapeutics, a wholly-owned subsidiary of Scopus, will release scientific data during the 17th Annual Meeting of the Oligonucleotide Therapeutics Society. The meeting will conclude on Wednesday, September 29, 2021.

    Alan Horsager, Ph.D., President and Chief Executive Officer of Duet and President — Immuno-Oncology of Scopus, will present DUET-01: Bispecific Oligonucleotide Targeting TLR9 and STAT3 Signaling for B Cell Lymphoma Immunotherapy as part of Session VIII: Oligonucleotide Preclinical

    NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that Duet Therapeutics, a wholly-owned subsidiary of Scopus, will release scientific data during the 17th Annual Meeting of the Oligonucleotide Therapeutics Society. The meeting will conclude on Wednesday, September 29, 2021.

    Alan Horsager, Ph.D., President and Chief Executive Officer of Duet and President — Immuno-Oncology of Scopus, will present DUET-01: Bispecific Oligonucleotide Targeting TLR9 and STAT3 Signaling for B Cell Lymphoma Immunotherapy as part of Session VIII: Oligonucleotide Preclinical I.

    Dr. Horsager has also presented Bifunctional Oligonucleotides for Systemic Treatment of Immunologically Cold Solid Tumors as an Industry Talk.

    Duet has also released a video depicting the mechanism of action for its proprietary CpG-STAT3 inhibitors, which can be viewed here, to coincide with Duet's presentations at the OTS Meeting.

    About the Duet Platform

    Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Olimmune was acquired by Scopus in June 2021. Duet is a wholly-owned subsidiary of Scopus.

    The Duet Platform is comprised of three distinctive, complementary CpG-STAT3 inhibitors:

    •  RNA silencingCpG-STAT3siRNA("DUET-01")
    •  AntisenseCpG-STAT3ASO("DUET-02")
    •  DNA-binding inhibitorCpG-STAT3decoy("DUET-03")

    DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file two INDs for DUET-02 in Q4 2022 in genitourinary and head & neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.

    About Scopus BioPharma

    Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. The company's lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. Additional STAT3-targeting immunotherapy drug candidates include bifunctional antisense and DNA-binding inhibition therapies. In addition, the company is developing additional drug candidates that target the endocannabinoid system, including MRI-1867 for the treatment systemic sclerosis. The company also seeks to identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions. Receive updates by following Scopus BioPharma on Twitter here.

    Forward-Looking Statements

    This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company's Form 10-K for the fiscal year ended December 31, 2020, as amended, filed with the U.S. Securities and Exchange Commission ("SEC")) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Further, there can be no assurance that the company will identify and/or consummate any transaction relating to any additional technologies.

    Contacts

    Rodd Leeds/David Waldman

    Crescendo Communications, LLC

    Tel: (212) 671-1020

    Email: SCPS@crescendo-ir.com

    Hugh Burns/Delia Cannan/Nicholas Leasure

    Reevemark

    Tel: (212) 433-4600

    Email: scopus@reevemark.com



    Primary Logo

    View Full Article Hide Full Article
View All Scopus BioPharma Inc. News